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Abstract The positive strand RNA coronavirus, infectious
bronchitis virus (IBV), induces a G2/M phase arrest and reduc-
tion in the G1 and G1/S phase transition regulator cyclin D1.
Quantitative real-time RT-PCR and Western blot analysis
demonstrated that cyclin D1 was reduced post-transcriptionally
within infected cells independently of the cell-cycle stage at the
time of infection. Confocal microscopy revealed that cyclin D1
decreased in IBV-infected cells as infection progressed and inhi-
bition studies indicated that a population of cyclin D1 could be
targeted for degradation by a virus mediated pathway. In con-
trast to the SARS-coronavirus, IBV nucleocapsid protein did
not interact with cyclin D1.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
The ordered growth and division of cells is described as the
cell cycle, which can be separated into a number of distinct
phases, gap 1 (G1), synthesis (S), gap 2 (G2) and mitosis
(M) [1] followed by cytokinesis [2]. Each stage of the cell cycle
is regulated and controlled by both positive and negative reg-
ulators, for example cyclins and their partner molecules, the
cyclin dependent kinases (CDKs) and associated inhibitor
complexes (CDKIs) [3]. Many viruses interact with the cell
cycle to promote favourable conditions for virus infection
and for disrupting host cell proliferation and function [4].
However, the alteration of the host cell cycle by RNA viruses
has not been described as extensively when compared to DNA
or retroviruses.
Coronaviruses are a family of positive strand RNA viruses
which replicate in the cytoplasm of infected cells and belong
to the order Nidovirales [5]. Infection of cells with the avian
coronavirus infectious bronchitis virus (IBV) causes a G2/M
phase arrest [6], with changes in the amounts of proteins in-
volved in cell cycle regulation, such as a reduction in cyclin
D1 [6]. In the case of the murine coronavirus, mouse hepatitis
virus (MHV), infection results in an arrest in the G0/G1 phase
of the cell cycle with a resulting decrease in the D-type cyclins
[7]. Over-expression studies indicated that a component of the
viral replicase could arrest cells in this phase of the cell cycle
[8]. On the other hand, in patients infected with severe acute
respiratory syndrome (SARS) coronavirus hepatocytes have
been reported to accumulate in mitosis [9] and this is in
contrast to a number of SARS-coronavirus proteins that when
over expressed lead to an accumulation of cells in the G0/G1
phase of the cell cycle [10,11]. For example, the SARS-corona-
virus nucleocapsid (N) protein has been reported to block
S phase progression [12] and prolong the G0/G1 phase
and shorten the S phase [13]. Likewise, when over expressed
the IBV N protein delays cell growth and results in aberrant
cytokinesis [14,15], which is also observed in infected cells
[6,15].
Cyclin D1, when complexed with either CDK 4 or 6, posi-
tively regulates progression of cells through the G1-S phase
of the cell cycle. Like all cyclins, levels of cyclin D1 ﬂuctuate
depending on the particular stage of the cell cycle, with levels
of cyclin D1 accumulating in the G1 phase. Cyclin D1 is then
rapidly degraded via the cellular proteosome during S phase
allowing DNA synthesis to occur [16]. Levels then begin to rise
again during the G2 and M phases of the cell cycle. Regulation
of cyclin D1 expression is controlled by the abundance of cy-
clin D1 mRNA, sub-localisation and degradation [17]. In this
study the reduction of cyclin D1 was investigated in IBV in-
fected cells.
2. Materials and methods
2.1. Cells and viruses
The growth and titration of IBV Beaudette-US, an embryo-adapted
IBV strain [18], and the growth of Vero cells were performed as de-
scribed previously [6]. Cell culture experiments were performed within
sub-conﬂuent cells to avoid artefact G0/G1 populations due to contact
inhibition and in the absence of antibiotic or anti-fungal agents. Cells
were infected with IBV at 2 · 106 pfu/ml (MOI = 1) at 70% conﬂuent
and incubated for 1 h at 37 C, after which the virus was replaced with
cell growth media. UV inactivation of IBV was performed as described
previously [6].
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2.2. Vero cell enrichment
Vero cells were cell-cycle enriched as described previously [6] by ser-
um deprivation (G0), double thymidine treatment (G1/S) and noco-
dazole treatment (G2/M) [6]. The eﬃciency of cell cycle
synchronisation was determined by ﬂow cytometric analysis [6].
2.3. Treatment of cells with LiCl and MG132
Vero cells were seeded at 2 · 105 and grown to 70% conﬂuency be-
fore being mock or IBV infected at 2 · 106 pfu/ml. At 8 h post infec-
tion the cells were treated with 10 lM MG132 or 0.5, 1, 2.5 or
5 mM LiCl or a combination of both where detailed. At 24 h post
infection the cells were lysed and total cellular protein quantiﬁed by
BCA assay. Western blot analysis was then performed using antibod-
ies against cyclin D1, GAPDH and IBV proteins. Alternatively, cells
were ﬁxed and made permeable for subsequent immunoﬂuoresence
analysis.
2.4. Leptomycin B (LMB) treatment of cells
Mock and IBV-infected Vero cells were treated with 2.5 ng/ml LMB
at 1 h post infection. At 16 h post infection, cells were processed as
appropriate either for Western blot or immunoﬂuoresence analysis.
Fig. 1. Western blot analysis of cyclin D1 (A) and IBV proteins (B) in mock-infected (mock) or cells infected with IBV (IBV) or treated with UV-
inactivated IBV (UV). Time post infection is indicated above the respective lane and the migration of molecular weight markers is indicated to the
left. Equal protein loading was conﬁrmed by Western blot analysis of GAPDH. The data shown is one of three separate experiments. (C) TaqMan
analysis of the amount of cyclin D1 mRNA at the indicated times (h) in asynchronously (AS) replicating cells either mock (M) or infected with IBV
(I) or treated with UV-inactivated virus (UV).
Table 1
Real time RT-PCR analysis of IBV genomic RNA levels during a 24 h
infection in Vero cells as shown by corrected 40-Ct values
Time post-infection (h) Correct 40-Ct values
0 0
1 12.704 ± 0.391
4 10.336 ± 0.045
8 14.545 ± 0.183
12 15.076 ± 0.119
24 16.068 ± 0.124
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LMB activity was shown using a previously described luciferase assay
[19] and carried out in triplicate.
2.5. Transient cell transfection and plasmids
Vero cells were cultured in six well plates until 70% conﬂuent, then
transfected with l lg of plasmid DNA using Lipofectamine transfec-
tion reagent (Invitrogen). The constructs utilised in this study,
pEGFP-IBVN or PEGFP-IBVNDNES, were used for the expression
of either wild type N protein or N protein in which nuclear export sig-
nal has been deleted, are fused to EGFP [20–22]. The ECFP-cyclin D1
fusion protein expression plasmid, pECFP-cyclin D1 was constructed
by amplifying human cyclin D1 from a Gateway Destination Vector
(pEXP1-dest) (Invitrogen) containing cyclin D1, using the following
primers which incorporated a SacII and XhoI restriction: Forward:
5 0 GGAATATTCTCGAGCGATGGAACACCAGCTC 3 0 and Re-
verse 5 0 TTATTATTCCGCGGCTAGATGTCCACGTC 3 0, before
being ligated into pECFP-C1 (cyan ﬂuorescent protein).
2.6. Western blot analysis
Mock, UV inactivated virus treated and IBV infected Vero cells were
harvested 24 h post-infection and lysed with radioimmuoprecipitation
(RIPA) buﬀer. Total protein was quantiﬁed by BCA assay (Promega)
and 10 lg of total protein from each sample was analyzed by Western
blot [6]. IBV proteins were detected with chicken anti-IBV polyclonal
sera (1:20000, Charles River). Cyclin D1 was detected with a rabbit
anti-cyclin D1 polyclonal antibody (1:500, Santa Cruz). Mouse anti-
GAPDH (6C5) monoclonal antibody (1:40000, AbCam) was used to
detect glyceraldehyde-3-phosphatedehydrogenase (GAPDH).
Fig. 2. (A) Propidium iodide (PI) plot and BrdU/PI staining of cell cycle proﬁles of cells enriched in the G0 phase of the cell cycle using serum
starvation (for the latter plot the X-axis is the intensity of PI staining and the Y-axis is the intensity of BrdU staining). (B) Western blot analysis of
GAPDH, cyclin D1 and IBV proteins in mock infected cells (Mock) and cells treated with UV-inactivated virus (UV) and infectious virus (IBV) at
the times indicated post-infection (h) in cells enriched in the GO phase of the cell cycle and then released. The migration of molecular weight markers
is indicated to the left. (C) TaqMan analysis of the amount of cyclin D1 mRNA in cells enriched in the G0 phase of the cell cycle (indicated G0) and
then released at the indicated times (h), in either mock (M) or cells infected with IBV (I) or treated with UV-inactivated virus (UV).
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2.7. Cellular RNA preparation
Total cellular RNA was extracted at 0 h and 24 h post-infection by
the RNeasy method (Qiagen).
2.8. Taqman analysis of cyclin D1 mRNA
Cyclin D1 mRNA levels in mock, IBV infected and cells treated with
UV-inactivated virus were quantiﬁed by TaqMan real time PCR.
Primers and probes for both cyclin D1 and 28S were designed using
the Primer Express software program (Applied Biosystems). Cyclin
D1 forward primer: GTGAACAAGCTCAAGTGGAACCT; reverse
primer: TGGCATTTTGGAAAGGAAGTG; probe: TGACCCCGC-
ACGATTTCATCGA. 28S forward primer: GGCGAAAGACTAA-
TCGAACCAT; reverse primer: CGAGAGCGCCAGCTATCCT;
probe: TAGTAGCTGGTTCCCTCCGAAGTTTCCCT and experi-
ments performed as described previously [23,24]. Where appropriate
these probes were designed across exon–exon boundaries so no geno-
mic DNA or unprocessed RNA would be ampliﬁed. IBV genomic
RNA was quantiﬁed using previously describe primer/probe sets: for-
ward primer: CGTACCGGTTCTGTTGTGTGA; reverse primer:
GCCCAACGCTAGGCTCAA and probe: TCACCTCCCCCCACA-
TACCTCTAAGGG [25]. Quantiﬁcation was based on increased ﬂuo-
rescence detected due the 5 0 exonuclease activity of the Taq DNA
polymerase during PCR ampliﬁcation hydrolysing the target speciﬁc
probes. The reporter signal was normalised by the reference dye 6-car-
boxy-c-rhodamine, which was not actually involved in ampliﬁcation.
Results were expressed in terms of Ct values (threshold cycle value);
the cycle at which the change in reporter dye passes a signiﬁcance
threshold (DRn).
Fig. 3. (A) Propidium iodide (PI) plot and BrdU/PI staining of cell cycle proﬁles of cells enriched in the G1/S phase of the cell cycle using a double-T
block (for the latter plot the X-axis is the intensity of PI staining and the Y-axis is the intensity of BrdU staining). (B) Western blot analysis of
GAPDH, cyclin D1 and IBV proteins in mock infected cells (Mock) and cells treated with UV-inactivated virus (UV) and infectious virus (IBV) at
the times indicated post-infection (h) in cells enriched in the G1/S phase of the cell cycle and then released. The migration of molecular weight
markers is indicated to the left. (C) TaqMan analysis of the amount of cyclin D1 mRNA in cells enriched in the G1/S phase of the cell cycle (indicated
G1S) and then released at the indicated times (h), in either mock (M) or cells infected with IBV (I) or treated with UV-inactivated virus (UV).
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Variation in sampling and RNA preparation was accounted for by
standardising the Ct values for gene-speciﬁc products for each sample
to the Ct value of 28S rRNA product for the same sample. RNA levels
between samples in the same experiment were normalised by pooling
values from all samples in that experiment and calculating the mean
Ct value for 28S rRNA-speciﬁc gene product. Variations in each indi-
vidual 28S rRNA sample compared to the mean were then calculated.
Diﬀerences in input of total RNA were calculated by determining the
slope of the 28S rRNA log10 dilution series regression line. Using the
slopes of the respective gene speciﬁc or 28S rRNA log10 dilution series
regression lines, the diﬀerence in input total RNA, as represented by
the 28S rRNA, was then used to adjust the gene speciﬁc Ct values [25].
This was done as follows:
Corrected Ct value ¼ Ct þ ðN t  C0tÞS=S 0
where Ct is the mean sample Ct; Nt is the experimental 28S mean; C
0
t is
the mean 28S of sample; S is the IBV 5 0 UTR/IBV 3 0UTR slope; and
S 0 is the 28S slope.
Results were then expressed as 40-Ct values.
2.9. Analysis of the sub-cellular localisation of native cyclin D1
Confocal sections were captured using a Zeiss LSM 510 Meta laser
scanning confocal microscope [26]. Native cyclin D1 was labelled with
rabbit anti cyclin D1 (1:200, Santa Cruz) and detected with either goat
anti rabbit FITC (1:200, Sigma) (green) or chicken anti rabbit Texas
Red (1:200, Sigma) (red). Where appropriate, IBV-infected cells were
ﬁxed post-infection and IBV proteins were labelled with chicken
anti-IBV polyclonal sera (1:200, Charles River) and detected with rab-
bit anti chicken antibody conjugated to AlexaFluor633 (Molecular
Fig. 4. (A) Propidium iodide (PI) plot and BrdU/PI staining of cell cycle proﬁles of cells enriched in the G2/M phase of the cell cycle using
nocodazole (for the latter plot the X-axis is the intensity of PI staining and the Y-axis is the intensity of BrdU staining). (B) Western blot analysis of
GAPDH, cyclin D1 and IBV proteins in mock infected cells (Mock) and cells treated with UV-inactivated virus (UV) and infectious virus (IBV) at
the times indicated post-infection (h) in cells enriched in the G2/M phase of the cell cycle and then released. The migration of molecular weight
markers is indicated to the left. (C) TaqMan analysis of the amount of cyclin D1 mRNA in cells enriched in the G2/M phase of the cell cycle
(indicated G2M) and then released at the indicated times (h), in either mock (M) or cells infected with IBV (I) or treated with UV-inactivated virus
(UV).
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Probes/Invitrogen 1:200) (far red). Images were scanned four times. No
cross talk between channels was determined by switching oﬀ the appro-
priate excitation laser and imaging the corresponding emission. In cells
co-transfected with pEGFP-IBVN and pECFP-cyclin D1 the respec-
tive fusion proteins were analyzed by meta-confocal microscopy
[21,27].
3. Results and discussion
To determine whether the reduction of cyclin D1 protein was
caused by replicating virus or as a cellular response to the pres-
ence of virus particles, the amount of cyclin D1 protein from
IBV infected or UV-inactivated virus treated cells was com-
pared to that of mock-infected cells (Fig. 1A). Densitometric
analysis indicated there was an approximately 14-fold reduc-
tion in the level of cyclin D1 protein in IBV-infected cells com-
pared to either mock-infected or cells treated with UV-
inactivated virus (data not shown). This data are in contrast
to the retrovirus, HIV, and DNA virus, cytomegalovirus,
which can cause cell cycle perturbations in the absence of rep-
licating virus [28,29]. UV-inactivation of IBV was determined
by Western blot analysis to detect viral proteins (Fig. 1A)
and RT-PCR to viral RNA (data not shown). No viral RNA
or their products were detected in cells treated with UV-inac-
tivated virus.
Real-time RT-PCR (TaqMan) was used to quantify the
amount of cyclin D1 mRNA between mock-infected, UV-inac-
tivated virus treated and IBV-infected cells. Total RNA was
prepared from the three separate experiments and cyclin D1
mRNA from each sample analyzed in triplicate. Representa-
tive data from one experiment is shown (Fig. 1B). There was
no signiﬁcant diﬀerence in the level of cyclin D1 mRNA
Fig. 5. Confocal microscopy analysis of the sub-cellular localisation of cyclin D1 (green) in mock and IBV-infected (red) asynchronously replicating
cells at the times indicated post-infection. Antibody controls are also presented with the corresponding transmission phase contrast images.
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between each population, suggesting the reduction of cyclin
D1 in IBV-infected cells is post-transcription. To conﬁrm that
real-time RT-PCR could distinguish between diﬀerent levels of
RNA, the amount of virus RNA was assayed at 0, 1, 4, 8, 12
and 24 h pi, using primer and probe sets to detect viral geno-
mic RNA. The results indicated that there was an approxi-
mately 8-fold increase in viral genomic RNA between 1 and
24 h post-infection (each 40-Ct value indicates a twofold diﬀer-
ence) (Table 1) and demonstrated that real-time RT-PCR can
distinguish changes in RNA levels.
Although IBV will infect dividing cells one of the major tar-
gets of infection is the upper epithelial cell layer [30] which con-
tains quiescent cells in the G0 phase of the cell cycle. In order
to model this, Vero cells were enriched in the G0 phase of the
cell cycle by serum starvation which was conﬁrmed by ﬂow
cytometry [6] (Fig. 2A), resulting in an average of 87% of cells
in the G0 phase, 10% in the S phase and 3% in the G2/M phase
of the cell cycle. This compared to non-conﬂuent asynchro-
nously growing cells, in which an average of 58% of cells are
in G0/G1, 38% in S phase and 4% in the G2/M phase (data
not shown and [6]). The cells were then simultaneously released
and treated with either UV-inactivated virus or infected with
IBV and the levels of cyclin D1 protein (determined by Wes-
tern blot) and mRNA (determined by TaqMan as per above)
compared to that of mock-infected cells at 24 h post-infection
and release. The data indicated that the amount of cyclin D1
protein was reduced in IBV infected cells compared to
mock-infected or UV-inactivated virus treated cells (Fig. 2B).
However, the level of cyclin D1 mRNA was not signiﬁcantly
diﬀerent for cells either treated with IBV or UV-inactivated
virus or left untreated (Fig. 2C). However, there was an
approximately fourfold increase (two 40-Ct values) in cyclin
D1 mRNA in these cells compared to cells at 0 h (Fig. 2C),
which may reﬂect an increase in mRNA and protein synthesis
due to entry into the cell cycle.
Cyclin D1 mainly functions during the G1 phase and at the
G1/S phase transition before being rapidly degraded via the
ubiquitin pathway during S phase [17]. Cyclin D1 levels then
begin to rise again in the G2/M phase. Therefore, we investi-
gated the eﬀect on cyclin D1 mRNA and protein in IBV-in-
fected cells which had been enriched at either the G1/S or
G2/M phase border. Vero cells were enriched in these phases
Fig. 6. (A) Western blot analysis of cyclin D1, IBV and GAPDH proteins in mock-infected or virus infected (IBV) cells treated with various of
concentrations of LiCl (indicated). The data shown is one of three separate experiments which had identical results. (B) Confocal microscopy analysis
of the sub-cellular localisation of cyclin D1 (green) in mock and IBV-infected (red) asynchronously replicating cells treated with 0 and 5 mM LiCl.
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using, either a double thymidine block or nocodazole treat-
ment [6]. After treatment, cell cycle proﬁles were determined
using dual ﬂow cytometry and the data indicated that the cells
had been enriched at the G1/S or G2/M phase border (Figs. 3A
and 4A, respectively). For double thymidine treated cells there
were an average of 88% of cells in the G1 phase, 3% in S phase
and 9% in the G2/M phase, and in cells treated with nocodaz-
ole, there were an average of 20% of cells in G1, 23% in S
phase and 57% in the G2/M phase, as described previously
[6]. The cells were then simultaneously released and treated
with either UV-inactivated virus or infected with IBV and
the levels of cyclin D1 protein (determined by Western blot)
and mRNA (determined by TaqMan as per above) compared
to that of mock-infected cells at 24 h post-infection and re-
lease. The data indicated that the amount of cyclin D1 protein
was reduced in IBV-infected cells compared to mock-infected
or UV-inactivated virus treated cells for both cell cycle condi-
tions (Figs. 3B and 4B). There was no signiﬁcant diﬀerence in
the levels of cyclin D1 mRNA for both conditions (Figs. 3C
and 4C). This mirrored the observations of cyclin D1 protein
and mRNA in asynchronously growing and G0 enriched Vero
cells, and indicated that reduction in cyclin D1 levels by IBV
was not dependent on the cell cycle stage at the time of infec-
tion. Interestingly, in the cells enriched in the G2/M phase of
the cell cycle whilst the amount of cyclin D1 protein was
greater in mock-infected cells at 24 h post-infection compared
Fig. 7. (A) Histogram showing the activity of LMB in relation to its eﬀect to inhibit CRM1 mediated export of HIV-1 Rev protein. The ﬁrst and
third columns are where the luciferase reporter RNA construct is expressed in combination with the HIV-1 Rev protein (plasmid pRev, denoted
Rev). Whereas the second column and fourth columns are where the luciferase reporter RNA construct (plasmid pLUCSALRRE) is expressed in the
absence of the HIV-1 Rev protein. The third and fourth columns is data from LMB positive cells (indicated +LMB) whereas the ﬁrst and second
column is data derived from cells not treated with LMB (indicated LMB). (B) Confocal microscopy analysis of cyclin D1 (green) in mock-infected
and IBV-infected (red) asynchronously replicating cells either untreated or treated with LMB. (C) Western blot analysis of cyclin D1, IBV and
GAPDH proteins in mock-infected or IBV-infected asynchronously replicating cells either untreated or treated with LMB.
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to 0 h, in infected cells the amount of cyclin D1 remained un-
changed compared to that at 0 h. This result could be attrib-
uted to the fact that in uninfected cycling cells cyclin D1 is
rapidly degraded in S phase and then increases again in the
G2 phase [31], whereas IBV arrests cells in the early G2 phase
of the cell cycle [6] and therefore cyclin D1 levels may not have
started to increase.
Previous Western blot data indicated that cyclin D1 protein
levels were signiﬁcantly reduced in infected cells by 24 h post-
infection [6]. Immunoﬂuoresence analysis of cyclin D1 in in-
fected cells indicated that cyclin D1 protein was less than in
mock-infected cells from 4 h post-infection and was absent
from the nucleus by 24 h post-infection, reﬂecting the Western
blot analysis (Fig. 5). However, at early time points there are
insuﬃcient cells infected to distinguish cyclin D1 changes by
Western blot analysis. Therefore, to study the degradation of
cyclin D1 protein by Western blot analysis coupled to confocal
microscopy time points post-16 h infection were utilised.
In replicating cells, cyclin D1 can be phosphorylated on
Thr286 by glycogen synthase kinase 3 beta (GSK3b) promot-
ing nuclear export and subsequent degradation in the cyto-
plasm [32,33]. However, cyclin D1 can also be exported for
degradation independently of GSK3b via unknown mecha-
nisms [34]. To distinguish between these two possibilities, cells
were either mock or infected with IBV and then treated at 8 h
post-infection with varying concentrations of LiCl, which have
been shown to decrease GSK3b activity [35].
Western blot analysis was used to detect cyclin D1, IBV and
GAPDH proteins. The data indicated that the amount of cy-
clin D1 protein was greater in LiCl treated mock-infected cells
compared to IBV-infected cells (Fig. 6A) and this was reﬂected
in the accumulation of nuclear cyclin D1 as revealed immuno-
ﬂuoresence analysis (Fig. 6B). Increasing concentrations of
LiCl resulted in a dose dependent increase in the amount of cy-
clin D1 protein in both mock and infected cells. This indicated
that there was a population of cyclin D1 whose nuclear export
was GSK3b dependent. However, in IBV infected LiCl treated
cells the amount of cyclin D1 was less than in mock-infected
cells and therefore indicated that a population of cyclin D1
was still being targeted for degradation.
Cyclin D1 is exported from the nucleus to the cytoplasm via
the exportin CRM-1 [36,37]. To test whether this was the case
in IBV-infected cells, mock and infected cells were treated with
the CRM-1 inhibitor, leptomycin B (LMB). To conﬁrm that
the LMB treatment was active in these experiments, an RNA
export assay was used based on the export of HIV-1 REV that
utilizes the CRM1 pathway [19]. A luciferase gene was placed
within an ineﬃciently spliced intron that contained the REV
response element (creating plasmid pLUCSALRRE). The
pre-mRNA is normally retained in the nucleus and the ex-
ported, spliced mRNA lacks the luciferase gene. Export is
facilitated through co-expressing HIV-1 Rev protein under
the control of a CMV promoter (plasmid pRev), which ensures
that the pre-mRNA is actively exported through the CRM1
pathway and luciferase activity would therefore be detected.
The presence of LMB would inhibit the REV-dependent
mRNA export, conﬁrming that LMB treatment of cells was
eﬀectively blocking the CRM1-dependent export pathway.
Therefore, in order to assess the activity of LMB Vero cells
were transfected with pLUCSALRRE with or without LMB
and also in the absence and presence of pRev (Fig. 7A). The
data indicated that in the absence of pRev there was no signif-
icant diﬀerence in luciferase activity between LMB treated or
untreated cells, and this level was taken as background activ-
ity. In contrast, when the pRev protein was present, the level
of luciferase was 70% less in LMB treated cells compared to
untreated cells, indicating that LMB reduced CRM1-mediated
export.
Immunoﬂuoresence analysis indicated that in mock-infected
cells in the presence or absence of LMB cyclin D1 was retained
in the nucleus (Fig. 7B). Whereas in the presence of LMB in
infected cells cyclin D1 was observed in the nucleus, although
to a lesser extent. (Fig. 7B). The stabilising aﬀect of LMB on
cyclin D1 in infected cells was conﬁrmed by Western blot anal-
ysis (Fig. 7C).
To test whether degradation of cyclin D1 in virus infected
cells was mediated via the cellular proteosomal pathway cells
were either mock or infected with IBV or treated with UV-
inactivated virus, and then treated 8 h post-infection with the
proteosomal inhibitor MG132. This inhibitor has been used
to investigate ubiquitin mediated degradation of cyclin D1 in
Fig. 8. (A). Western blot analysis of cyclin D1, IBV N and GAPDH
proteins in mock (M) and virus infected (I) or cells treated with UV-
inactivated virus (UV) at 24 h post-infection. Treatment MG132 is
denoted (+) and untreated (). (B) Confocal microscopy analysis of
cyclin D1 (green) in mock-infected and IBV-infected (red) asynchro-
nously replicating cells either untreated or treated with MG132.
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coxsackie virus infected cells [38]. Western blot analysis was
used to detect cyclin D1, GAPDH and IBV proteins. The data
indicated more cyclin D1 protein in MG132 treated cells com-
pared to untreated (Fig. 8A), which was conﬁrmed by immu-
noﬂuoresence analysis of both mock and infected cells in the
presence and absence of MG132 (Fig. 8B). This indicated that
in both mock and IBV infected cells the degradation of cyclin
D1 was dependent on the cellular proteosomal pathway. How-
ever, as the amount of cyclin D1 in IBV infected cells was less
than in mock infected cells treated with MG132 there may be a
population of cyclin D1 that is being degraded via an unknown
mechanism. In the presence of 5 mM LiCl and 10 lM MG132
cyclin D1 levels were part stabilised in IBV infected cells as re-
vealed by both Western blot and immunoﬂuoresence analysis
(Fig. 9A and B, respectively) (although there as variation on
a cell to cell basis indicated by immunoﬂuoresence).
Although the treatment of infected cells with LiCl, MG132
or LMB results in the increased stabilisation of cyclin D1 com-
pared to untreated infected cells, there is still less cyclin D1
than when compared to mock-infected treated cells, indicating
that a viral protein and/or signalling pathway may be respon-
sible for the export of cyclin D1 from the nucleus to the cyto-
plasm for its subsequent degradation. One candidate viral
protein, could be the IBV N protein which can traﬃc between
the nucleolus and the cytoplasm [22,26] and interactions with
the nucleolus and its proteins may be one mechanism by which
RNA viruses can disrupt the cell cycle [39]. IBV N protein is a
phospho-protein which binds RNA with high aﬃnity [40,41].
In the case of the severe acute respiratory syndrome coronavi-
rus (SARS-CoV), N protein has been shown to interact with
cyclin D1 in cells expressing N protein [12]. To investigate
whether IBV N protein could interact with cyclin D1 co-local-
isation studies using confocal microscopy and pull down stud-
ies were performed. However, no co-localisation was observed
in cells expressing IBV N protein tagged to the ﬂuorescent fu-
sion protein, EGFP (Fig. 10A). This may have been due to the
fact that IBV N protein localises principally to the cytoplasm
and nucleolus, rather than the nucleus [26,42], which is in con-
trast to cyclin D1 which is predominately nuclear, therefore the
two molecules could not interact. To test this hypothesis a mu-
tant EGFP-tagged N protein was used in which the nuclear ex-
port signal had been deleted and whose localisation was
nuclear and nucleolar [26]. However, no co-localisation was
observed (Fig. 10B). Likewise, cyclin D1 was tagged N-termi-
nally with ECFP, which resulted in the accumulation of the fu-
sion protein predominately in the cytoplasm. Transfection of
cells with this plasmid and also expressing EGFP-IBV N pro-
tein indicated that no co-localisation was observed between
these two proteins in the cytoplasm (Fig. 10C).
No interaction was also found with a biochemical pull down
of cell extracts using a recombinant his-tagged N protein
[40,43] anchored to a solid matrix as a target (data not shown).
Whereas as a control N protein could pull down the tumour
suppressor protein p53 (Fig. 10D) which we have shown previ-
Fig. 9. (A) Western blot analysis of cyclin D1, IBV N and GAPDH proteins in mock (M) and virus-infected (I) asynchronously replicating cells at
24 h post-infection treated with LiCl (at the concentrations indicated) and with 10 uMMG132. (B) Confocal microscopy analysis of cyclin D1 (green)
in mock-infected and IBV-infected (red) asynchronously replicating cells treated with 5 mM LiCl and 10 uM MG132.
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ously co-localises with N protein [44]. Likewise IBV N protein
co-localises with and can pull down nucleolin [15,26]. The pos-
sibility remains that other viral proteins could direct the traf-
ﬁcking of cyclin D1 from the nucleus to the cytoplasm.
This study demonstrated that actively replicating IBV is re-
quired to decrease cyclin D1 and that this change is regulated
post-transcription. This may be mediated by the arrest in the
G2 phase of the cell cycle of infected cells prior to the stage
when cyclin D1 levels would usually begin to rise. Further-
more, in infected cells cyclin D1 is redistributed from the nu-
cleus to the cytoplasm, where we hypothesize it is targeted
for degradation, by a viral protein dependent traﬃcking path-
way. However, the precise mechanism of this pathway remains
to be determined.
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